Methyl-CpG binding domain protein 2 (Mbd2) drives breast cancer progression through the modulation of epithelial-to-mesenchymal transition.
Journal
Experimental & molecular medicine
ISSN: 2092-6413
Titre abrégé: Exp Mol Med
Pays: United States
ID NLM: 9607880
Informations de publication
Date de publication:
01 Apr 2024
01 Apr 2024
Historique:
received:
04
12
2022
accepted:
25
01
2024
revised:
27
12
2023
medline:
1
4
2024
pubmed:
1
4
2024
entrez:
31
3
2024
Statut:
aheadofprint
Résumé
Methyl-CpG-binding domain protein 2 (Mbd2), a reader of DNA methylation, has been implicated in different types of malignancies, including breast cancer. However, the exact role of Mbd2 in various stages of breast cancer growth and progression in vivo has not been determined. To test whether Mbd2 plays a causal role in mammary tumor growth and metastasis, we performed genetic knockout (KO) of Mbd2 in MMTV-PyMT transgenic mice and compared mammary tumor progression kinetics between the wild-type (PyMT-Mbd2
Identifiants
pubmed: 38556549
doi: 10.1038/s12276-024-01205-2
pii: 10.1038/s12276-024-01205-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre)
ID : PJT-156225
Organisme : Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre)
ID : MOP 130410
Organisme : Gouvernement du Canada | Instituts de Recherche en Santé du Canada | CIHR Skin Research Training Centre (Skin Research Training Centre)
ID : MOP 130410
Informations de copyright
© 2024. The Author(s).
Références
Nishiyama, A. & Nakanishi, M. Navigating the DNA methylation landscape of cancer. Trends Genet. 37, 1012–1027 (2021).
pubmed: 34120771
doi: 10.1016/j.tig.2021.05.002
Parry, A., Rulands, S. & Reik, W. Active turnover of DNA methylation during cell fate decisions. Nat. Rev. Genet. 22, 59–66 (2021).
pubmed: 33024290
doi: 10.1038/s41576-020-00287-8
Mahmood, N. & Rabbani, S. A. DNA methylation readers and cancer: mechanistic and therapeutic applications. Front. Oncol. 9, 489 (2019).
pubmed: 31245293
pmcid: 6579900
doi: 10.3389/fonc.2019.00489
Greenberg, M. V. C. & Bourc’his, D. The diverse roles of DNA methylation in mammalian development and disease. Nat. Rev. Mol. Cell Biol. 20, 590–607 (2019).
pubmed: 31399642
doi: 10.1038/s41580-019-0159-6
Hanahan, D. Hallmarks of cancer: new dimensions. Cancer Discov. 12, 31–46 (2022).
pubmed: 35022204
doi: 10.1158/2159-8290.CD-21-1059
Silverman, L. R. et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J. Clin. Oncol. 20, 2429–2440 (2002).
pubmed: 12011120
doi: 10.1200/JCO.2002.04.117
Cheishvili, D., Boureau, L. & Szyf, M. DNA demethylation and invasive cancer: implications for therapeutics. Br. J. Pharmacol. 172, 2705–2715 (2015).
pubmed: 25134627
pmcid: 4439869
doi: 10.1111/bph.12885
Jones, P. A., Issa, J.-P. J. & Baylin, S. Targeting the cancer epigenome for therapy. Nat. Rev. Genet. 17, 630 (2016).
pubmed: 27629931
doi: 10.1038/nrg.2016.93
Ateeq, B., Unterberger, A., Szyf, M. & Rabbani, S. A. Pharmacological inhibition of DNA methylation induces proinvasive and prometastatic genes in vitro and in vivo. Neoplasia (N.Y., N.Y.) 10, 266–278 (2008).
doi: 10.1593/neo.07947
Fraga, M. F. et al. The affinity of different MBD proteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic acids Res. 31, 1765–1774 (2003).
pubmed: 12626718
pmcid: 152853
doi: 10.1093/nar/gkg249
Hendrich, B., Guy, J., Ramsahoye, B., Wilson, V. A. & Bird, A. Closely related proteins MBD2 and MBD3 play distinctive but interacting roles in mouse. Dev. Genes Dev. 15, 710–723 (2001).
pubmed: 11274056
doi: 10.1101/gad.194101
Sansom, O. J. et al. Deficiency of Mbd2 suppresses intestinal tumorigenesis. Nat. Genet. 34, 145–147 (2003).
pubmed: 12730693
doi: 10.1038/ng1155
Zhou, M. et al. MBD2 ablation impairs lymphopoiesis and impedes progression and maintenance of T-ALL. Cancer Res. 78, 1632–1642 (2018).
pubmed: 29330145
doi: 10.1158/0008-5472.CAN-17-1434
Campbell, P. M., Bovenzi, V. & Szyf, M. Methylated DNA-binding protein 2 antisense inhibitors suppress tumourigenesis of human cancer cell lines in vitro and in vivo. Carcinogenesis 25, 499–507 (2004).
pubmed: 14688029
doi: 10.1093/carcin/bgh045
Liu, Z. et al. Hypoxia-Induced Suppression of Alternative Splicing of MBD2 Promotes Breast Cancer Metastasis via Activation of FZD1Suppression of MBD2 Splicing Promotes Breast Cancer Metastasis. Cancer Res. 81, 1265–1278 (2021).
pubmed: 33402389
doi: 10.1158/0008-5472.CAN-20-2876
Mian, O. Y. et al. Methyl-binding domain protein 2–dependent proliferation and survival of breast cancer cells. Mol. Cancer Res. 9, 1152–1162 (2011).
pubmed: 21693597
pmcid: 3157569
doi: 10.1158/1541-7786.MCR-11-0252
Cheishvili, D. et al. Synergistic effects of combined DNA methyltransferase inhibition and MBD2 depletion on breast cancer cells; MBD2 depletion blocks 5-aza-2ʹ-deoxycytidine-triggered invasiveness. Carcinogenesis 35, 2436–2446 (2014).
pubmed: 25178277
pmcid: 4216057
doi: 10.1093/carcin/bgu181
Day, C.-P., Merlino, G. & Van Dyke, T. Preclinical mouse cancer models: a maze of opportunities and challenges. Cell 163, 39–53 (2015).
pubmed: 26406370
pmcid: 4583714
doi: 10.1016/j.cell.2015.08.068
Guy, C. T., Cardiff, R. & Muller, W. J. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12, 954–961 (1992).
pubmed: 1312220
pmcid: 369527
Fantozzi, A. & Christofori, G. Mouse models of breast cancer metastasis. Breast Cancer Res. 8, 212 (2006).
pubmed: 16887003
pmcid: 1779475
doi: 10.1186/bcr1530
Lin, E. Y. et al. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am. J. Pathol. 163, 2113–2126 (2003).
pubmed: 14578209
pmcid: 1892434
doi: 10.1016/S0002-9440(10)63568-7
Fluck, M. M. & Schaffhausen, B. S. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol. Mol. Biol. Rev. 73, 542–563 (2009).
pubmed: 19721090
pmcid: 2738132
doi: 10.1128/MMBR.00009-09
Mahmood, N. et al. uPAR antibody (huATN-658) and Zometa reduce breast cancer growth and skeletal lesions. Bone Res. 8, 1–12 (2020).
doi: 10.1038/s41413-020-0094-3
Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (San. Diego, Calif.) 25, 402–408 (2001).
pubmed: 11846609
doi: 10.1006/meth.2001.1262
Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat. methods 9, 357 (2012).
pubmed: 22388286
pmcid: 3322381
doi: 10.1038/nmeth.1923
Zhang, Y. et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 9, 1–9 (2008).
doi: 10.1186/gb-2008-9-9-r137
Heinz, S. et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. cell 38, 576–589 (2010).
pubmed: 20513432
pmcid: 2898526
doi: 10.1016/j.molcel.2010.05.004
Kamburov, A., Stelzl, U., Lehrach, H. & Herwig, R. The ConsensusPathDB interaction database: 2013 update. Nucleic acids Res. 41, D793–D800 (2013).
pubmed: 23143270
doi: 10.1093/nar/gks1055
Kim, D., Langmead, B. & Salzberg, S. L. HISAT: a fast spliced aligner with low memory requirements. Nat. methods 12, 357–360 (2015).
pubmed: 25751142
pmcid: 4655817
doi: 10.1038/nmeth.3317
Pertea, M. et al. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat. Biotechnol. 33, 290–295 (2015).
pubmed: 25690850
pmcid: 4643835
doi: 10.1038/nbt.3122
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. bioinformatics 26, 139–140 (2010).
pubmed: 19910308
doi: 10.1093/bioinformatics/btp616
Kong, L. et al. CPC: assess the protein-coding potential of transcripts using sequence features and support vector machine. Nucleic acids Res. 35, W345–W349 (2007).
pubmed: 17631615
pmcid: 1933232
doi: 10.1093/nar/gkm391
Sun, L. et al. Utilizing sequence intrinsic composition to classify protein-coding and long non-coding transcripts. Nucleic acids Res. 41, e166–e166 (2013).
pubmed: 23892401
pmcid: 3783192
doi: 10.1093/nar/gkt646
Searle, B. C. Scaffold: a bioinformatic tool for validating MS/MS-based proteomic studies. Proteomics 10, 1265–1269 (2010).
pubmed: 20077414
doi: 10.1002/pmic.200900437
Tuominen, V. J., Ruotoistenmäki, S., Viitanen, A., Jumppanen, M. & Isola, J. ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67. Breast cancer Res. : BCR 12, R56–R56 (2010).
pubmed: 20663194
pmcid: 2949645
doi: 10.1186/bcr2615
Mahmood, N. et al. Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications. Oncotarget 9, 5169–5183 (2018).
pubmed: 29435170
doi: 10.18632/oncotarget.23704
Chandrashekar, D. S. et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 25, 18–27 (2022).
pubmed: 35078134
pmcid: 8788199
doi: 10.1016/j.neo.2022.01.001
Cheng, L. et al. Deletion of MBD2 inhibits proliferation of chronic myeloid leukaemia blast phase cells. Cancer Biol. Ther. 19, 676–686 (2018).
pubmed: 29565710
pmcid: 6067900
doi: 10.1080/15384047.2018.1450113
Kim, M. Y. et al. Rational discovery of antimetastatic agents targeting the intrinsically disordered region of MBD2. Sci. Adv. 5, eaav9810 (2019).
pubmed: 31799386
pmcid: 6867884
doi: 10.1126/sciadv.aav9810
Liu, Z. et al. Hypoxia-induced suppression of alternative splicing of MBD2 promotes breast cancer metastasis via activation of FZD1. Cancer Res. 81, 1265–1278 (2021).
pubmed: 33402389
doi: 10.1158/0008-5472.CAN-20-2876
Lax, E. et al. Methyl-CpG binding domain 2 (Mbd2) is an epigenetic regulator of autism-risk genes and cognition. Transl. Psychiatry 13, 259 (2023).
pubmed: 37443311
pmcid: 10344909
doi: 10.1038/s41398-023-02561-9
Zou, Z., Ohta, T., Miura, F. & Oki, S. ChIP-Atlas 2021 update: a data-mining suite for exploring epigenomic landscapes by fully integrating ChIP-seq, ATAC-seq and Bisulfite-seq data. Nucleic Acids Res. 1, 175–182 (2022).
doi: 10.1093/nar/gkac199
Zhou, Y. et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat. Commun. 10, 1523 (2019).
pubmed: 30944313
pmcid: 6447622
doi: 10.1038/s41467-019-09234-6
Hondermarck, H. Neurotrophins and their receptors in breast cancer. Cytokine Growth Factor Rev. 23, 357–365 (2012).
pubmed: 22749855
doi: 10.1016/j.cytogfr.2012.06.004
Ueda, K., Arakawa, H. & Nakamura, Y. Dual-specificity phosphatase 5 (DUSP5) as a direct transcriptional target of tumor suppressor p53. Oncogene 22, 5586–5591 (2003).
pubmed: 12944906
doi: 10.1038/sj.onc.1206845
Li, N. et al. Forkhead-box A3 (FOXA3) represses cancer stemness and partially potentiates chemosensitivity by targeting metastasis-associated in colon cancer 1 (MACC1) signaling pathway in colorectal cancer cells. Curr Cancer Drug Targets, https://doi.org/10.2174/1568009620666201207150632 (2020).
Kurz, S. et al. The anti-tumorigenic activity of A2M-A lesson from the naked mole-rat. PLoS One 12, e0189514 (2017).
pubmed: 29281661
pmcid: 5744951
doi: 10.1371/journal.pone.0189514
Dang, T. T. et al. ΔNp63α induces the expression of FAT2 and Slug to promote tumor invasion. Oncotarget 7, 28592–28611 (2016).
pubmed: 27081041
pmcid: 5053748
doi: 10.18632/oncotarget.8696
Zoppino, F. C. M., Guerrero-Gimenez, M. E., Castro, G. N. & Ciocca, D. R. Comprehensive transcriptomic analysis of heat shock proteins in the molecular subtypes of human breast cancer. BMC Cancer 18, 700 (2018).
pubmed: 29954368
pmcid: 6022707
doi: 10.1186/s12885-018-4621-1
Stefansson, O. A. & Esteller, M. BRCA1 as a tumor suppressor linked to the regulation of epigenetic states: keeping oncomiRs under control. Breast Cancer Res 14, 304 (2012).
pubmed: 22423979
pmcid: 3446364
doi: 10.1186/bcr3119
Djebali, S. et al. Landscape of transcription in human cells. Nature 489, 101–108 (2012).
pubmed: 22955620
pmcid: 3684276
doi: 10.1038/nature11233
Barr, H. et al. Mbd2 contributes to DNA methylation-directed repression of the Xist gene. Mol. Cell Biol. 27, 3750–3757 (2007).
pubmed: 17353271
pmcid: 1900000
doi: 10.1128/MCB.02204-06
Phesse, T. J. et al. Deficiency of Mbd2 attenuates Wnt signaling. Mol. Cell Biol. 28, 6094–6103 (2008).
pubmed: 18644872
pmcid: 2547016
doi: 10.1128/MCB.00539-08
He, T.-C. et al. Identification of c-MYC as a target of the APC pathway. Science 281, 1509–1512 (1998).
pubmed: 9727977
doi: 10.1126/science.281.5382.1509
Zhao, M., Liu, Y., Zheng, C. & Qu, H. dbEMT 2.0: An updated database for epithelial-mesenchymal transition genes with experimentally verified information and precalculated regulation information for cancer metastasis. J. Genet Genomics 46, 595–597 (2019).
pubmed: 31941584
doi: 10.1016/j.jgg.2019.11.010
Loh, C. Y. et al. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: Signaling, Therapeutic Implications, and Challenges. Cells 8, https://doi.org/10.3390/cells8101118 (2019).
Jing, Y. et al. SPARC promotes the proliferation and metastasis of oral squamous cell carcinoma by PI3K/AKT/PDGFB/PDGFRβ axis. J. Cell. Physiol. 234, 15581–15593 (2019).
pubmed: 30706473
doi: 10.1002/jcp.28205
Deng, S., Zhang, L., Li, J., Jin, Y. & Wang, J. Activation of the PI3K-AKT signaling pathway by SPARC contributes to the malignant phenotype of cholangiocarcinoma cells. Tissue Cell 76, 101756 (2022).
pubmed: 35217388
doi: 10.1016/j.tice.2022.101756
Hao, C. et al. OPN promotes the aggressiveness of non-small-cell lung cancer cells through the activation of the RON tyrosine kinase. Sci. Rep. 9, 1–14 (2019).
doi: 10.1038/s41598-019-54843-2
Le Naour, A. et al. EO771, the first luminal B mammary cancer cell line from C57BL/6 mice. Cancer Cell Int. 20, 1–13 (2020).
doi: 10.1186/s12935-020-01418-1
Mahmood, N., Arakelian, A., Cheishvili, D., Szyf, M. & Rabbani, S. A. S‐adenosylmethionine in combination with decitabine shows enhanced anti‐cancer effects in repressing breast cancer growth and metastasis. J. Cell. Mol. Med. 24, 10322–10337 (2020).
pubmed: 32720467
pmcid: 7521255
doi: 10.1111/jcmm.15642
Shang, S. et al. MBD2a–NuRD binds to the methylated γ-globin gene promoter and uniquely forms a complex required for silencing of HbF expression. Proc. Natl Acad. Sci. 120, e2302254120 (2023).
pubmed: 37307480
pmcid: 10288633
doi: 10.1073/pnas.2302254120
Croci, D. O. et al. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol., Immunother. 56, 1687–1700 (2007).
pubmed: 17571260
doi: 10.1007/s00262-007-0343-y
Wood, K. H. & Zhou, Z. Emerging molecular and biological functions of MBD2, a reader of DNA methylation. Front. Genet. 7, 93 (2016).
pubmed: 27303433
pmcid: 4880565
doi: 10.3389/fgene.2016.00093
Wang, L. et al. Mbd2 promotes foxp3 demethylation and T-regulatory-cell function. Mol. Cell Biol. 33, 4106–4115 (2013).
pubmed: 23979593
pmcid: 3811679
doi: 10.1128/MCB.00144-13
Wang, Y. et al. MBD2 serves as a viable target against pulmonary fibrosis by inhibiting macrophage M2 program. Sci. Adv. 7, eabb6075 (2021).
pubmed: 33277324
pmcid: 7775789
doi: 10.1126/sciadv.abb6075
Wang, Y. et al. The methyl-CpG-binding domain 2 facilitates pulmonary fibrosis by orchestrating fibroblast to myofibroblast differentiation. Eur. Resp. J. 60, 2003697 (2022).
doi: 10.1183/13993003.03697-2020
Millet, C. & Zhang, Y. E. Roles of Smad3 in TGF-beta signaling during carcinogenesis. Crit. Rev. Eukaryot. Gene Expr. 17, 281–293 (2007).
pubmed: 17725494
pmcid: 2639747
doi: 10.1615/CritRevEukarGeneExpr.v17.i4.30
Zhang, Y. et al. Analysis of the NuRD subunits reveals a histone deacetylase core complex and a connection with DNA methylation. Genes Dev. 13, 1924–1935 (1999).
pubmed: 10444591
pmcid: 316920
doi: 10.1101/gad.13.15.1924
Devailly, G. et al. Dynamics of MBD2 deposition across methylated DNA regions during malignant transformation of human mammary epithelial cells. Nucleic Acids Res. https://doi.org/10.1093/nar/gkv508 (2015).
Baubec, T., Ivanek, R., Lienert, F. & Schubeler, D. Methylation-Dependent and -Independent Genomic Targeting Principles of the MBD Protein Family. Cell 153, 480–492 (2013).
pubmed: 23582333
doi: 10.1016/j.cell.2013.03.011
Stefanska, B. et al. Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res, 0008-5472.CAN-10-3823 [pii]10.1158/0008-5472.CAN-10-3823 (2011).
Stefanska, B. et al. Transcription onset of genes critical in liver carcinogenesis is epigenetically regulated by methylated DNA-binding protein MBD2. Carcinogenesis 34, 2738–2749 (2013).
pubmed: 23955541
doi: 10.1093/carcin/bgt273
Roche, J. (Multidisciplinary Digital Publishing Institute, 2018).
Zhang, L. et al. MBD2 facilitates tumor metastasis by mitigating DDB2 expression. Cell Death Dis. 14, 303 (2023).
pubmed: 37142578
pmcid: 10160113
doi: 10.1038/s41419-023-05804-1
Sangaletti, S. et al. Osteopontin shapes immunosuppression in the metastatic niche. Cancer Res. 74, 4706–4719 (2014).
pubmed: 25035397
doi: 10.1158/0008-5472.CAN-13-3334
Sangaletti, S. et al. SPARC Is a New Myeloid-Derived Suppressor Cell Marker Licensing Suppressive Activities. Front Immunol. 10, 1369 (2019).
pubmed: 31281314
pmcid: 6596449
doi: 10.3389/fimmu.2019.01369
Dongre, A., Ortiz-Cuaran, S. & Korkaya, H. The role of the EMT program in regulating the immune response in carcinoma. Front. Immunol. 13, 940164 (2022).
pubmed: 35707530
pmcid: 9189401
doi: 10.3389/fimmu.2022.940164
Zhu, D. et al. BAI1 Suppresses Medulloblastoma Formation by Protecting p53 from Mdm2-Mediated Degradation. Cancer Cell 33, 1004–1016.e1005 (2018).
pubmed: 29894688
pmcid: 6002773
doi: 10.1016/j.ccell.2018.05.006